ClinicalTrials.gg
CompletedNCT06846528Updated Apr 29, 2025

A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants

A Phase 1 interventional study of AZD2389 and Itraconazole in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.

Read the detailed description

This study will be an open-label, fixed sequence, Drug-Drug Interaction (DDI) study consisting of 3 periods.

The study will comprise:

  • A screening period of maximum 28 days
  • Period 1
  • Period 2
  • Period 3
  • A Follow-up Visit 7 to 14 days after the last PK sample has been collected.
02

Conditions studied

  • Healthy Participants

Keywords

  • Fibroblast Activation Protein inhibitor
  • Advanced hepatic fibrosis
  • Chronic liver disease
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  • Females of non- must be for at least 12 months or have documentation of irreversible surgical sterilization.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the methods.
  • Have a (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Abnormal laboratory values, clinically important abnormalities or abnormal vital signs
  • Any positive result on screening for serum surface antigen/antibody, , or .
  • Current smokers (within 3 months prior to screening visit) or history of alcohol and drug abuse
  • History of severe allergy or
  • Excessive intake of caffeine-containing drinks or food
  • Use of drugs with enzyme inducing properties or use of any prescribed or nonprescribed medication including antacids, analgesics
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    AZD2389 and Itraconazole

    AZD2389 is dosed on days 1 and 6. Itraconazole is dosed on days 3,4,5,6,7, with the dose on day 6 coming after AZD2389.

    Drug: AZD2389 · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed drug concentration (Cmax) of AZD2389

    To assess the effect of itraconazole on the Cmax of AZD2389.

    Time frame: Day 1 to Day 8

  2. Area under concentration-timecurve from time zero to infinity (AUCinf) of AZD2389

    To assess the effect of itraconazole on the AUCinf of AZD2389.

    Time frame: Day 1 to Day 8

  3. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of AZD2389

    To assess the effect of itraconazole on the AUClast of AZD2389.

    Time frame: Day 1 to Day 8

Secondary outcomes

  1. Apparent total body clearance (CL/F) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole

    Time frame: Day 1 to Day 8

  2. Apparent volume of distribution based on the terminal phase (Vz/F) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole

    Time frame: Day 1 to Day 8

  3. Terminal elimination half-life (t1/2λz) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  4. Time to reach maximum observed concentration (tmax) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  5. Ratio of Test treatment (AZD2389 + itraconazole) to Reference (AZD2389) based on Cmax (RCmax) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  6. Ratio of Test treatment (AZD2389 + itraconazole) to Reference (AZD2389) based on AUClast (RAUClast) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  7. Ratio of Test treatment (AZD2389 + itraconazole) to Reference (AZD2389) based on AUCinf (RAUCinf) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  8. Renal Clearance (CLR) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  9. Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 (Ae(t1-t2)) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  10. Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe(t1-t2)) of AZD2389

    To describe the plasma PK of AZD2389 when AZD2389 is administered alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  11. Percent change from baseline in fibroblast activation protein (FAP) inhibition

    To evaluate the pharmacodynamics (PD) of AZD2389 by assessment of inhibition of FAP activity in plasma after single oral dose of AZD2389 alone or in combination with itraconazole.

    Time frame: Day 1 to Day 8

  12. Number of participants with Adverse Events (AEs)

    To assess the safety and tolerability of a single oral dose of AZD2389 alone or in combination with itraconazole in healthy participants.

    Time frame: From Screening (Day -29 to Day -2) up to 8 weeks

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Apr 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Feb 26, 2025
Primary completionActual
Apr 23, 2025
CompletionActual
Apr 23, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06846528
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Feb 26, 2025
Primary completion
Apr 23, 2025
Completion
Apr 23, 2025
Last update
Apr 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion